XML 22 R77.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidating Financial Statements (Schedule of Condensed Consolidating Statements of Comprehensive Income) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 27, 2019
Jun. 28, 2019
Mar. 29, 2019
Sep. 28, 2018
Jun. 29, 2018
Mar. 30, 2018
Sep. 27, 2019
Sep. 28, 2018
Condensed Consolidating Financial Statements                
Net sales $ 743.7     $ 799.9     $ 2,357.6 $ 2,380.7
Cost of sales 419.4     433.5     1,309.3 1,272.8
Gross profit 324.3     366.4     1,048.3 1,107.9
Selling, general and administrative expenses 205.7     193.4     661.8 594.5
Research and development expenses 103.1     86.1     268.0 260.7
Restructuring charges, net 7.2     14.8     11.2 101.8
Non-restructuring impairment charges 0.0     2.0     113.5 2.0
Loss on divestiture 0.0     0.6     0.0 0.6
Operating income (loss) [1] 8.3     69.5     (6.2) 148.3
Interest expense (77.6)     (93.6)     (231.8) (280.1)
Interest income 2.9     2.0     6.6 6.6
Other income, net 37.9     13.4     128.6 17.8
Intercompany Interest And Fees 0.0     0.0     0.0 0.0
Income (Loss) from Equity Method Investments 0.0     0.0     0.0 0.0
Loss from continuing operations before income taxes (28.5)     (8.7)     (102.8) (107.4)
Income tax benefit (27.6)     (122.9)     (256.6) (203.9)
(Loss) income from continuing operations (0.9)     114.2     153.8 96.5
(Loss) income from discontinued operations, net of income taxes (0.2)     (0.4)     6.8 14.9
Net (loss) income (1.1) $ 6.8 $ 154.9 113.8 $ 15.6 $ (18.0) 160.6 111.4
Other Comprehensive Income (Loss), Net of Tax (2.0)     3.0     1.7 (4.3)
Comprehensive Income (Loss) (3.1)     116.8     162.3 107.1
Mallinckrodt plc                
Condensed Consolidating Financial Statements                
Net sales 0.0     0.0     0.0 0.0
Cost of sales 0.4     0.7     1.7 1.6
Gross profit (0.4)     (0.7)     (1.7) (1.6)
Selling, general and administrative expenses 10.0     12.4     35.2 30.1
Research and development expenses 1.6     1.6     4.8 3.8
Restructuring charges, net 0.0     0.0     0.0 0.0
Non-restructuring impairment charges       0.0     0.0 0.0
Loss on divestiture       0.0       0.0
Operating income (loss) (12.0)     (14.7)     (41.7) (35.5)
Interest expense (1.4)     (1.6)     (14.0) (6.2)
Interest income 2.5     2.4     17.5 6.8
Other income, net 0.2     2.3     8.9 9.0
Intercompany Interest And Fees (4.6)     (3.5)     (14.6) (12.0)
Income (Loss) from Equity Method Investments 12.7     127.8     200.8 145.9
Loss from continuing operations before income taxes (2.6)     112.7     156.9 108.0
Income tax benefit (1.5)     (1.1)     (3.7) (3.4)
(Loss) income from continuing operations (1.1)     113.8     160.6 111.4
(Loss) income from discontinued operations, net of income taxes 0.0     0.0     0.0 0.0
Net (loss) income (1.1)     113.8     160.6 111.4
Other Comprehensive Income (Loss), Net of Tax (2.0)     3.0     1.7 (4.3)
Comprehensive Income (Loss) (3.1)     116.8     162.3 107.1
Mallinckrodt International Finance S.A.                
Condensed Consolidating Financial Statements                
Net sales 0.0     0.0     0.0 0.0
Cost of sales 0.0     0.0     0.0 0.0
Gross profit 0.0     0.0     0.0 0.0
Selling, general and administrative expenses 0.6     0.1     1.2 0.5
Research and development expenses 0.0     0.0     0.0 0.0
Restructuring charges, net 0.0     0.0     0.0 0.0
Non-restructuring impairment charges       0.0     0.0 0.0
Loss on divestiture       0.0       0.0
Operating income (loss) (0.6)     (0.1)     (1.2) (0.5)
Interest expense (60.2)     (112.0)     (192.3) (323.2)
Interest income 0.1     249.6     0.4 251.6
Other income, net 12.9     (156.8)     43.6 (154.0)
Intercompany Interest And Fees (0.1)     (0.1)     (0.1) (0.1)
Income (Loss) from Equity Method Investments 80.6     238.9     448.7 647.2
Loss from continuing operations before income taxes 32.7     219.5     299.1 421.0
Income tax benefit 3.3     (2.4)     9.9 (4.4)
(Loss) income from continuing operations 29.4     221.9     289.2 425.4
(Loss) income from discontinued operations, net of income taxes 0.1     0.0     2.8 0.0
Net (loss) income 29.5     221.9     292.0 425.4
Other Comprehensive Income (Loss), Net of Tax (2.0)     3.0     1.7 (4.3)
Comprehensive Income (Loss) 27.5     224.9     293.7 421.1
Other Subsidiaries                
Condensed Consolidating Financial Statements                
Net sales 743.7     799.9     2,357.6 2,380.7
Cost of sales 419.0     432.8     1,307.6 1,271.2
Gross profit 324.7     367.1     1,050.0 1,109.5
Selling, general and administrative expenses 195.1     180.9     625.4 563.9
Research and development expenses 101.5     84.5     263.2 256.9
Restructuring charges, net 7.2     14.8     11.2 101.8
Non-restructuring impairment charges       2.0     113.5 2.0
Loss on divestiture       0.6       0.6
Operating income (loss) 20.9     84.3     36.7 184.3
Interest expense (72.7)     (257.4)     (209.2) (272.2)
Interest income 57.0     27.4     172.4 69.7
Other income, net 24.8     167.9     76.1 162.8
Intercompany Interest And Fees 4.7     3.6     14.7 12.1
Income (Loss) from Equity Method Investments 29.5     221.9     292.0 425.4
Loss from continuing operations before income taxes 64.2     247.7     382.7 582.1
Income tax benefit (29.4)     (119.4)     (262.8) (196.1)
(Loss) income from continuing operations 93.6     367.1     645.5 778.2
(Loss) income from discontinued operations, net of income taxes (0.3)     (0.4)     4.0 14.9
Net (loss) income 93.3     366.7     649.5 793.1
Other Comprehensive Income (Loss), Net of Tax (4.3)     5.8     2.4 (9.3)
Comprehensive Income (Loss) 89.0     372.5     651.9 783.8
Eliminations                
Condensed Consolidating Financial Statements                
Net sales 0.0     0.0     0.0 0.0
Cost of sales 0.0     0.0     0.0 0.0
Gross profit 0.0     0.0     0.0 0.0
Selling, general and administrative expenses 0.0     0.0     0.0 0.0
Research and development expenses 0.0     0.0     0.0 0.0
Restructuring charges, net 0.0     0.0     0.0 0.0
Non-restructuring impairment charges       0.0     0.0 0.0
Loss on divestiture       0.0       0.0
Operating income (loss) 0.0     0.0     0.0 0.0
Interest expense 56.7     277.4     183.7 321.5
Interest income (56.7)     (277.4)     (183.7) (321.5)
Other income, net 0.0     0.0     0.0 0.0
Intercompany Interest And Fees 0.0     0.0     0.0 0.0
Income (Loss) from Equity Method Investments (122.8)     (588.6)     (941.5) (1,218.5)
Loss from continuing operations before income taxes (122.8)     (588.6)     (941.5) (1,218.5)
Income tax benefit 0.0     0.0     0.0 0.0
(Loss) income from continuing operations (122.8)     (588.6)     (941.5) (1,218.5)
(Loss) income from discontinued operations, net of income taxes 0.0     0.0     0.0 0.0
Net (loss) income (122.8)     (588.6)     (941.5) (1,218.5)
Other Comprehensive Income (Loss), Net of Tax 6.3     (8.8)     (4.1) 13.6
Comprehensive Income (Loss) $ (116.5)     $ (597.4)     $ (945.6) $ (1,204.9)
[1]
The amount of operating loss included in the Company's unaudited condensed consolidated statement of income for the three and nine months ended September 28, 2018 related to the Sucampo Acquisition was $32.2 million and $99.9 million, respectively. Included within these results were $18.0 million and $45.0 million of amortization associated with intangibles recognized from this acquisition and $31.0 million and $77.5 million of expense associated with fair value adjustments of acquired inventory for the three and nine months ended September 28, 2018, respectively.